中生製藥(01177.HK)呼吸道感染藥獲國家藥監局一致性評價
中生製藥(01177.HK)公布,抗菌藥「鹽酸莫西沙星氯化鈉注射液」獲中國國家藥監局頒發藥品補充申請批准通知書,通過了仿製藥質量和療效一致性評價。
鹽酸莫西沙星氯化鈉注射液是最新一代(口奎)諾酮類抗菌藥,主要用於治療成人上呼吸道和下呼吸道感染,在呼吸科、急診科、外科、重症加強護理病房(ICU)、感染科等科室廣泛使用。鹽酸莫西沙星氯化鈉注射液具有抗菌譜廣、殺菌快速、耐藥率低、安全性高的特點,被中華醫學會《中國成人社區獲得性肺炎診斷和治療指南(2016版)》、世界衛生組織(WHO)《耐藥結核的治療指南》等權威指南推薦用於經驗性快速抗感染治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.